ArticleFrontiers in oncology2025
Predicting the recurrence risk of liver metastasis from colorectal cancer: a study based on preoperative CT intratumoral and peritumoral radiomics features.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to explore the value of predicting the recurrence risk of colorectal cancer liver metastasis (CRLM) based on preoperative CT intratumoral and peritumoral radiomics features. Methods: This study utilized retrospectively collected preoperative CT data of 201 CRLM patients, comprising 145 cases from the hospital one and 56 cases from an external hospital two. Liver metastases were precisely segmented via manual annotation. Subsequently, the intratumoral region of interest (ROI Results: Compared with SVM and RF, MLP demonstrated superior predictive performance for estimating the recurrence risk of CRLM patients. The best radiomics signatures for predicting the recurrence risk of CRLM were ROI Conclusion: Preoperative CT-based radiomics features extracted from intra-tumoral (ROI
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.